Literature DB >> 23391467

Fibulin-1 is down-regulated through promoter hypermethylation and suppresses renal cell carcinoma progression.

Wei Xiao1, Ji Wang, Heng Li, Wei Guan, Ding Xia, Gan Yu, Haibing Xiao, Bin Lang, Xin Ma, Jihong Liu, Xu Zhang, Zhangqun Ye, Hua Xu.   

Abstract

PURPOSE: Renal cell carcinoma is one of the most common cancers worldwide but the molecular mechanisms that underlie it are not fully understood. Fibulin-1, a multi-functional extracellular matrix protein, is involved in many types of cancer but its function in renal cell carcinoma is unclear. We investigated fibulin-1 expression and function in renal cell carcinoma.
MATERIALS AND METHODS: We performed real-time polymerase chain reaction, Western blot analysis and immunohistochemistry to determine fibulin-1 expression in renal cell carcinoma cells and patient tissues. Methylation specific polymerase chain reaction and quantitative sequencing were done to examine the methylation status of the FBLN1 gene promoter. Eukaryotic expression plasmid and a lentiviral vector were used to over express fibulin-1 in ACHN and 786-O renal cell carcinoma cells to investigate its function in vitro and in vivo.
RESULTS: Fibulin-1 was significantly down-regulated in renal cell carcinoma cell lines and patient tissues. Dysregulation was associated with renal cell carcinoma progression. The FBLN1 gene promoter region was hypermethylated and its methylation status correlated with fibulin-1 expression. Fibulin-1 over expression led dramatically to decreased cell growth, enhanced tumor cell apoptosis, decreased cell motility and angiogenesis in cultured renal cell carcinoma cells and in xenograft tumors in nude mice.
CONCLUSIONS: Fibulin-1 is down-regulated in renal cell carcinoma through promoter hypermethylation. It functions as a tumor suppressor and angiogenesis inhibitor in renal cell carcinoma.
Copyright © 2013 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23391467     DOI: 10.1016/j.juro.2013.01.098

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  20 in total

1.  Abnormal hypermethylation and clinicopathological significance of FBLN1 gene in cutaneous melanoma.

Authors:  Bao-Jin Wu; Zhao-Ping Zhou; Wen-Peng Li; Wei Ding; Ying-Zhi Wu; Zhong-Wen Zhou; Rong-Qing Zhang; Qing-Feng Liu; Hua Jiang
Journal:  Tumour Biol       Date:  2013-08-02

2.  Prognostic significance of promoter CpG island methylation of obesity-related genes in patients with nonmetastatic renal cell carcinoma.

Authors:  Julia Mendoza-Pérez; Jian Gu; Luis A Herrera; Nizar M Tannir; Shanyu Zhang; Surena Matin; Jose A Karam; Christopher G Wood; Xifeng Wu
Journal:  Cancer       Date:  2017-05-23       Impact factor: 6.860

3.  Low expression of fibulin-1 correlates with unfavorable prognosis in gastric cancer.

Authors:  Liang Feng; Chan Yao; Peng Li; Ying Feng; Fei Wang; Yi-Fei Liu; Yi-Bing Guo; Qin-Sheng Mao; Wan-Jiang Xue
Journal:  Tumour Biol       Date:  2016-01-16

4.  The cancer-retina antigen recoverin as a potential biomarker for renal tumors.

Authors:  Marina O Golovastova; Larisa V Tsoy; Anna V Bocharnikova; Dmitry O Korolev; Olga S Gancharova; Ekaterina A Alekseeva; Ekaterina B Kuznetsova; Lyudmila V Savvateeva; Elena E Skorikova; Vladimir V Strelnikov; Vladimir A Varshavsky; Andrey Z Vinarov; Vladimir N Nikolenko; Peter V Glybochko; Evgeni Yu Zernii; Andrey A Zamyatnin; Alexandr V Bazhin; Pavel P Philippov
Journal:  Tumour Biol       Date:  2016-01-26

Review 5.  Low level of plasma fibulin-1 in patients with thyroid lesions: a case-control study and literature review.

Authors:  Mehdi Hedayati; Raziyeh Abooshahab; S Adeleh Razavi; Pouya Salehipour; Kazem Ahmadikia; Seti Boroomand
Journal:  Mol Biol Rep       Date:  2020-10-26       Impact factor: 2.316

6.  Fibulin-1 is downregulated through promoter hypermethylation in colorectal cancer: a CONSORT study.

Authors:  Zhiying Xu; Hui Chen; Deliang Liu; Jirong Huo
Journal:  Medicine (Baltimore)       Date:  2015-04       Impact factor: 1.889

7.  KSHV microRNAs mediate cellular transformation and tumorigenesis by redundantly targeting cell growth and survival pathways.

Authors:  Rosalie Moody; Ying Zhu; Yufei Huang; Xiaodong Cui; Tiffany Jones; Roble Bedolla; Xiufen Lei; Zhiqiang Bai; Shou-Jiang Gao
Journal:  PLoS Pathog       Date:  2013-12-26       Impact factor: 6.823

Review 8.  The role of epigenetics in kidney malignancies.

Authors:  Alfredo Harb-De la Rosa; Matthew Acker; Sanjaya Swain; Murugesan Manoharan
Journal:  Cent European J Urol       Date:  2015-04-20

9.  Protocadherin17 Promoter Methylation is a Potential Predictive Biomarker in Clear Cell Renal Cell Carcinoma.

Authors:  Ying-Li Lin; Shi-Liang Gui; Hong Guo; Jian-Guo Ma; Wen-Ping Li
Journal:  Med Sci Monit       Date:  2015-09-25

10.  A Network Biology Approach Identifies Molecular Cross-Talk between Normal Prostate Epithelial and Prostate Carcinoma Cells.

Authors:  Victor Trevino; Alberto Cassese; Zsuzsanna Nagy; Xiaodong Zhuang; John Herbert; Philipp Antczak; Kim Clarke; Nicholas Davies; Ayesha Rahman; Moray J Campbell; Michele Guindani; Roy Bicknell; Marina Vannucci; Francesco Falciani
Journal:  PLoS Comput Biol       Date:  2016-04-28       Impact factor: 4.475

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.